Suppressor of cytokine signaling 5 (SOCS5)

Suppressor of cytokine signaling 5 (SOCS5) is a member of the SOCS protein family, characterized by a central SH2 domain and a SOCS box at the C-terminus. SOCS5 acts as a negative regulator of cytokine signaling, primarily by inhibiting Janus kinases (notably JAK1 and JAK2) and modulating specific cytokine receptor pathways such as the interleukin-4 receptor. It is broadly involved in the regulation of immune and inflammatory responses, as well as cellular proliferation, migration, and autophagy. SOCS5 plays context-dependent roles in disease, functioning as either a tumor suppressor or promoter depending on tissue and signaling context. High SOCS5 expression is associated with more aggressive tumor behavior and poorer prognosis in hepatocellular carcinoma, while deficiency in SOCS5 can lead to excessive inflammation and worsened outcomes in CNS viral infections[1][3][5][6]. There are no known clinically approved drugs that directly target SOCS5, but its modulation has therapeutic implications, particularly in oncology and infectious disease.

Other names

CIS6CISH5CISH6KIAA0671SOCS-5CIS-6Cytokine-inducible SH2 protein 6Cytokine-inducible SH2-containing protein 5

SOCS5 acts as a negative feedback inhibitor of cytokine receptor signaling. It inhibits Janus kinase (JAK) activity, particularly JAK1 and JAK2, and binds to cytokine receptors (e.g., IL-4 receptor α) to interfere with downstream signal transduction. Additionally, it regulates PI3K/Akt/mTOR and autophagy pathways.